Skip to search formSkip to main contentSkip to account menu

MK-7965

Known as: CDK inhibitor SCH 727965 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

dinaciclib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
Neuroblastoma (NB), the most common extracranial solid tumor of childhood, is responsible for approximately 15% of cancer-related… 
2015
2015
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
KRAS is activated by mutation in the vast majority of cases of pancreatic cancer; unfortunately, therapeutic attempts to inhibit… 
Highly Cited
2014
Highly Cited
2014
Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.
Highly Cited
2014
Highly Cited
2014
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Review
2014
Review
2014
Dinaciclib for the treatment of breast cancer
Introduction: Cyclin-dependent kinases (CDK) represent attractive targets in oncology due to their key role in controlling gene… 
2013
2013
andomized phase 2 study of the cyclin-dependent kinase inhibitor inaciclib ( MK-7965 ) versus erlotinib in patients with non-small cell ung cancer
Objectives: Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclindependent kinases, has been… 
Highly Cited
2012
Highly Cited
2012
Cyclin-dependent kinase inhibitors move into Phase III
  • Malini Guha
  • Nature Reviews Drug Discovery
  • 2012
  • Corpus ID: 34625364
After more than a decade of clinical development for cancer and numerous failures, Phase III trials of cyclin-dependent kinase… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License